Clinuvel Pharmaceuticals Ltd ADR (CLVLY)

OTC Markets


	Symbol		Exchange		Currency
	CLVLY		OTC Markets		USD	Delayed
	CLVLF		OTC Markets		USD	Delayed
	CUV		TradeGate		EUR	Delayed
	CUV		Sydney		AUD	Delayed

Currency in USD

7.530

+0.240(+3.29%)

Closed07:59:59

Fair Value

Day's Range

7.530

7.710

52 wk Range

6.800

11.400

CLVLY Income Statement

Featured here, the Income Statement (earnings report) for Clinuvel Pharmaceuticals Ltd ADR, showing the company's financial performance from operating and non operating activities such as revenue, expenses and income for the last 4 periods (either quarterly or annually).

Advanced Income Statement

Period Ending:

2015

30/06

2016

30/06

2017

30/06

2018

30/06

2019

30/06

2020

30/06

2021

30/06

2022

30/06

2023

30/06

2024

30/06

Total Revenues

32.57

48.32

65.72

78.32

88.18

Total Revenues Growth

+4.89%

+48.37%

+36.02%

+19.17%

+12.59%

Cost Of Revenues

7.3

4.17

9.25

7.52

7.73

Gross Profit

25.26

44.15

56.47

70.8

80.45

Gross Profit Growth

-17.44%

+74.73%

+27.92%

+25.37%

+13.62%

Gross Profit Margin %

77.58%

91.36%

85.92%

90.4%

91.23%

Other Operating Expenses, Total

13.01

15.58

20.92

26.67

31.88

	Other Operating Expenses, Total Growth
	R&D Expenses
	Selling General & Admin Expenses
	Other Operating Expenses

aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	-6.45%	+19.7%	+34.32%	+27.48%	+19.5%
aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	0.34	0.55	1.23	1.27	2.35
aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	12.23	14.17	19.15	24.64	28.95
aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	-	-	-0.22	-0.02	-0.56

Operating Income

12.25

28.57

35.55

44.13

48.57

Operating Income Growth

-26.6%

+133.19%

+24.43%

+24.14%

+10.07%

EBIT Margin %

37.62%

59.12%

54.09%

56.34%

55.08%

Net Interest Expenses

-1.49

-1.62

-1.83

0.71

2.87

Net Interest Expenses Growth

-374.32%

-8.54%

-13.09%

+138.96%

+302.53%

Interest Expense, Total

-2.05

-1.62

-2.27

-3.19

-4.45

Interest And Investment Income

0.56

-

0.44

3.91

7.32

Other Non Operating Expenses, Total

0.65

-1.37

0.6

0.74

-0.76

EBT, Excl. Unusual Items

11.41

25.58

34.32

45.58

50.68

Gain (Loss) On Sale Of Assets

-

-

-

-

-

Other Unusual Items, Total

0.13

0.13

-

-

-

EBT, Incl. Unusual Items

11.54

25.71

34.32

45.58

50.68

EBT, Incl. Unusual Items Growth

-36.29%

+122.8%

+33.48%

+32.8%

+11.19%

EBT, Incl. Unusual Items Margin

35.44%

53.22%

52.22%

58.19%

57.47%

Income Tax Expense

-3.51

0.98

13.44

14.97

15.04

Net Income to Company

15.05

24.73

20.88

30.6

35.64

Minority Interest

-

-

-

-

-

Net Income

15.05

24.73

20.88

30.6

35.64

Net Income Growth

-17%

+64.29%

-15.57%

+46.58%

+16.44%

Net Income Margin %

46.22%

51.18%

31.77%

39.08%

40.41%

Preferred Dividend and Other Adjustments

-

-

-

-

-

Net Income to Common Excl. Extra Items

15.05

24.73

20.88

30.6

35.64

Basic EPS - Continuing Operations

0.31

0.5

0.42

0.62

0.72

Basic EPS - Continuing Operations Growth

-18.8%

+63.79%

-15.57%

+46.58%

+15.45%

Diluted EPS - Continuing Operations

0.3

0.48

0.4

0.59

0.7

Diluted EPS - Continuing Operations Growth

-18.58%

+62.42%

-16.74%

+46.65%

+18.11%

Basic Weighted Average Shares Outstanding

49.26

49.41

49.41

49.41

49.83

Diluted Weighted Average Shares Outstanding

50.46

51.13

51.78

51.82

51.03

Dividend Per Share

0.03

0.03

0.04

0.05

0.05

Dividend Per Share Growth

0%

0%

+60%

+25%

0%

EBITDA

12.42

29.07

35.97

44.52

49.32

EBITDA Growth

-26.02%

+134.12%

+23.76%

+23.77%

+10.78%

EBITDA Margin %

38.12%

60.16%

54.74%

56.85%

55.93%

EBIT